• Volunteered to participate, cooperated with follow-up visits.

• Aged 18 - 75 years (inclusive), male or female.

• Histologically confirmed locally advanced resectable ESCC, clinically staged as Stage II - IVa (cT1N1-3M0, cT2-4aN0-3M0 before treatment; 8th AJCC), and achieve cCR/PR after 2 cycles of camrelizumab combined with nab-paclitaxel and carboplatin.

• Presence of measurable and/or non-measurable lesions as defined by RECIST 1.1;

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

• Estimated survival time ≥ 3 months.

• The function of major organs meets the following requirements:

‣ Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L;

⁃ Platelets ≥ 80×10\^9/L;

⁃ Hemoglobin ≥ 9g/dL;

⁃ Serum albumin ≥ 2.8g/dL;

⁃ Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or ALP ≤ 2.5 × ULN;

⁃ Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60mL/min;

⁃ International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5× ULN (subjects on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, and with INR within the expected therapeutic range of the anticoagulant can be screened);

• Patients of childbearing potential must use a medically approved contraceptive method (such as intrauterine device, contraceptive pills, or condoms) during the study treatment period and within 6 months after the end of the study treatment; serum Human Chorionic Gonadotropin (HCG) or urine HCG test must be negative within 72 hours before study enrollment; and must not be breastfeeding.